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BACKGROUND
Observational cohort studies and a secondary prevention trial have shown inverse asso-
ciations between adherence to the Mediterranean diet and cardiovascular risk.
METHODS
In a multicenter trial in Spain, we assigned 7447 participants (55 to 80 years of age, 57% 
women) who were at high cardiovascular risk, but with no cardiovascular disease at enroll-
ment, to one of three diets: a Mediterranean diet supplemented with extra-virgin olive oil, 
a Mediterranean diet supplemented with mixed nuts, or a control diet (advice to reduce 
dietary fat). Participants received quarterly educational sessions and, depending on group 
assignment, free provision of extra-virgin olive oil, mixed nuts, or small nonfood gifts. 
The primary end point was a major cardiovascular event (myocardial infarction, stroke, or 
death from cardiovascular causes). After a median follow-up of 4.8 years, the trial was 
stopped on the basis of a prespecified interim analysis. In 2013, we reported the results 
for the primary end point in the Journal. We subsequently identified protocol deviations, 
including enrollment of household members without randomization, assignment to a 
study group without randomization of some participants at 1 of 11 study sites, and appar-
ent inconsistent use of randomization tables at another site. We have withdrawn our 
previously published report and now report revised effect estimates based on analyses that 
do not rely exclusively on the assumption that all the participants were randomly assigned.
RESULTS
A primary end-point event occurred in 288 participants; there were 96 events in the group 
assigned to a Mediterranean diet with extra-virgin olive oil (3.8%), 83 in the group as-
signed to a Mediterranean diet with nuts (3.4%), and 109 in the control group (4.4%). 
In the intention-to-treat analysis including all the participants and adjusting for baseline 
characteristics and propensity scores, the hazard ratio was 0.69 (95% confidence interval 
[CI], 0.53 to 0.91) for a Mediterranean diet with extra-virgin olive oil and 0.72 (95% CI, 
0.54 to 0.95) for a Mediterranean diet with nuts, as compared with the control diet. Results 
were similar after the omission of 1588 participants whose study-group assignments were 
known or suspected to have departed from the protocol.
CONCLUSIONS
In this study involving persons at high cardiovascular risk, the incidence of major cardio-
vascular events was lower among those assigned to a Mediterranean diet supplemented 
with extra-virgin olive oil or nuts than among those assigned to a reduced-fat diet. 
(Funded by Instituto de Salud Carlos III, Spanish Ministry of Health, and others; Current 
Controlled Trials number, ISRCTN35739639.)
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The traditional Mediterranean diet is characterized by a high intake of olive oil, fruit, nuts, vegetables, and cereals; a 
moderate intake of fish and poultry; a low intake 
of dairy products, red meat, processed meats, 
and sweets; and wine in moderation, consumed 
with meals.1 In observational cohort studies2,3 
and a secondary prevention trial (the Lyon Diet 
Heart Study),4 increasing adherence to the Medi-
terranean diet has been consistently associated 
with lower cardiovascular risk.2-4 A systematic 
review ranked the Mediterranean diet as the 
most likely dietary model to provide protection 
against coronary heart disease.5 Small clinical 
trials have uncovered plausible biologic mecha-
nisms to explain the salutary effects of this 
food pattern.6-9 We designed a randomized trial, 
PREDIMED (Prevención con Dieta Mediterránea), 
to test the efficacy of two Mediterranean diets 
(one supplemented with extra-virgin olive oil and 
another with nuts), as compared with a control 
diet (advice on a low-fat diet), on primary cardio-
vascular prevention. Our original report was pub-
lished in the Journal in 2013.10 A 2017 analysis11 
of the distributions of baseline variables in ran-
domized trials identified the PREDIMED trial as 
having distributions that were significantly dif-
ferent from what would have been expected to 
result from randomization. This report led to our 
conducting a review of how participants were 
assigned to various intervention groups; that 
review revealed irregularities in our randomiza-
tion procedures. Therefore, we have withdrawn 
our original report12 and now publish a new report.
We describe the protocol deviations and re-
port revised intention-to-treat and per-protocol 
effect estimates that do not rely exclusively on 
the assumption that all the participants had 
been randomly assigned to the intervention 
groups. A detailed description of the changes 
that have been introduced and departures from 
the protocol is provided in the Supplementary 




The PREDIMED study was designed as a parallel-
group, multicenter, randomized trial. Details of 
the study design have been reported previous-
ly.13,14 The protocol, available at NEJM.org, was 
approved by the institutional review boards at all 
study locations. The authors vouch for the accu-
racy and completeness of the data and all analy-
ses and attest that this report accurately de-
scribes the conduct of the study as we know it.
Funding was provided by grants from Insti-
tuto de Salud Carlos III, Spanish Ministry of 
Health. Supplemental foods were donated, in-
cluding extra-virgin olive oil (by Hojiblanca and 
Patrimonio Comunal Olivarero, both in Spain), 
walnuts (by the California Walnut Commission), 
almonds (by Borges, in Spain), and hazelnuts (by 
Morella Nuts, in Spain). None of the sponsors 
had any role in the study design, data analysis, 
or reporting of the results.
Participant Selection and Randomization
Eligible participants were men (55 to 80 years of 
age) or women (60 to 80 years of age) with no 
cardiovascular disease at enrollment, who had 
either type 2 diabetes mellitus or at least three 
of the following major risk factors: smoking, 
hypertension, elevated low-density lipoprotein 
cholesterol levels, low high-density lipoprotein 
cholesterol levels, overweight or obesity, or a 
family history of premature coronary heart dis-
ease. Detailed enrollment criteria are provided on 
pages 18 and 19 in the Supplementary Appendix. 
All the participants provided written informed 
consent.
The protocol specified that participants were 
to be randomly assigned, in a 1:1:1 ratio, to one 
of three dietary intervention groups: a Mediter-
ranean diet supplemented with extra-virgin olive 
oil, a Mediterranean diet supplemented with nuts, 
or a control diet. Enrollment began on June 25, 
2003, and the last participant was recruited on 
June 30, 2009. The analyses in this report were 
based on a database locked as of September 2011 
and included primary end-point events occurring 
through December 1, 2010. Randomization was 
concealed with the use of closed envelopes8 dur-
ing part of the pilot phase of the study, but en-
velopes were not used for the remainder of the 
study. A computer-generated random-number 
sequence provided randomization tables for the 
11 participating sites, which encompassed 169 
clinics. These tables included four strata (men 
<70 years of age, men ≥70 years of age, women 
<70 years of age, and women ≥70 years of age) 
and were initially generated for 1000 partici-
pants (250 per stratum) for each site. We did not 
use blocks for randomization. Further details on 
the use of these tables at each of the 11 sites can 
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be found on pages 8 and 9 and 78 through 82 in 
the Supplementary Appendix. All the sites were 
given the same randomization sequence.
There were departures from the randomiza-
tion procedures that had been specified in the 
protocol that were not described in our original 
report. We included 425 participants who shared 
a household with a previously enrolled partici-
pant. These 425 participants were not randomly 
assigned but were assigned to the same interven-
tion as the member of the household who was 
already enrolled (Tables S2 and S3 in the Supple-
mentary Appendix). This was done to allow the 
recruitment of eligible household members and 
to avoid members of the same household being 
assigned to different diets. After the study had 
begun, the steering committee approved this 
protocol change. The protocol was not amended, 
and this protocol change was not described in 
the original report published in the Journal. In 
July 2017, we learned that at 1 of the 11 study 
sites (Site D), 467 participants were not randomly 
assigned as individual participants but instead 
were assigned according to clinic — that is, all 
the participants in each clinic received the same 
intervention (2 clinics assigned a Mediterranean 
diet with extra-virgin olive oil, 5 assigned a 
Mediterranean diet with nuts, and 4 assigned 
a control diet) (see pages 9 and 10 in the Supple-
mentary Appendix for additional details). In addi-
tion, review of the documentation about random-
ization procedures and of the actual assignments 
to the three groups suggested that the random-
ization tables were inconsistently used in another 
study site (Site B, 593 participants) (see pages 10 
and 11 in the Supplementary Appendix for details).
Interventions and Measurements
The dietary intervention8,13-15 is detailed on pages 
20 through 24 in the Supplementary Appendix. 
The specific recommended diets are summarized 
in Table 1. Participants in the group assigned to 
a Mediterranean diet with extra-virgin olive oil 
received 1 liter of the oil per week per house-
hold, with the recommendation to consume at 
least 4 tablespoons per day of extra-virgin olive 
oil per person. Participants in the group assigned 
to a Mediterranean diet with nuts received 30 g 
of mixed nuts per day per person (15 g of wal-
nuts, 7.5 g of hazelnuts, and 7.5 g of almonds) at 
no cost, and those in the control group received 
small nonfood gifts. No total calorie restriction 




Olive oil* ≥4 tbsp/day
Tree nuts and peanuts† ≥3 servings/wk
Fresh fruits ≥3 servings/day
Vegetables ≥2 servings/day
Fish (especially fatty fish), seafood ≥3 servings/wk
Legumes ≥3 servings/wk
Sofrito‡ ≥2 servings/wk
White meat Instead of red meat
Wine with meals (optionally, only for habitual drinkers) ≥7 glasses/wk
Discouraged
Soda drinks <1 drink/day
Commercial bakery goods, sweets, and pastries§ <2 servings/wk
Spread fats <1 serving/day
Red and processed meats <1 serving/day
Low-fat diet (control)¶
Recommended
Low-fat dairy products ≥3 servings/day
Bread, potatoes, pasta, rice ≥3 servings/day
Fresh fruits ≥3 servings/day
Vegetables ≥2 servings/day
Lean fish and seafood ≥3 servings/wk
Discouraged
Vegetable oils (including olive oil) ≤2 tbsp/day
Commercial bakery goods, sweets, and pastries§ ≤1 serving/wk
Nuts and fried snacks ≤1 serving/wk
Red and processed fatty meats ≤1 serving/wk
Visible fat in meats and soups‖ Always remove
Fatty fish, seafood canned in oil ≤1 serving/wk
Spread fats ≤1 serving/wk
Sofrito‡ ≤2 servings/wk
*  The amount of olive oil includes oil used for cooking and salads and oil con-
sumed in meals eaten outside the home. In the group assigned to the Mediter-
ranean diet with extra-virgin olive oil, the goal was to consume 50 g (approxi-
mately 4 tbsp) or more per day of the polyphenol-rich olive oil supplied, instead 
of the ordinary refined variety, which is poor in polyphenols. The participants 
received a free supply (15 liters every 3 months) to include the oil used for 
cooking and family needs.
†  For participants assigned to the Mediterranean diet with nuts, the recommend-
ed consumption was one daily serving (30 g, composed of 15 g of walnuts, 
7.5 g of almonds, and 7.5 g of hazelnuts). Participants received for free the 
needed allotments of tree nuts in packages of 2 kg of walnuts, 1 kg of almonds, 
and 1 kg of hazelnuts every 3 months, with the extra amounts to be shared 
with family members.
‡  Sofrito is a sauce made with tomato and onion, often including garlic and aro-
matic herbs, and slowly simmered with olive oil.
§  Commercial bakery goods, sweets, and pastries (not homemade) included cakes, 
cookies, biscuits, and custard.
¶  Up to September 2006, a brief personal recommendation and a leaflet with 
written guidelines to attain these goals (see page 53 in the Supplementary 
Appendix) were given to participants on a yearly basis. Starting in October 2006, 
the intensity of these recommendations was increased, including also group 
sessions and personal advice repeated every 3 months (i.e., with the same 
 intensity and frequency of contacts as in the two Mediterranean-diet groups). 
The composition of the recommended diet, however, was not changed.
‖  Participants were advised to remove the visible fat (or the skin) of chicken, 
duck, pork, lamb, or veal before cooking and the fat of soups, broths, and 
cooked meat dishes before consumption.
Table 1. Summary of Dietary Recommendations to Participants  
in the Mediterranean-Diet Groups and the Control-Diet Group.
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For participants in the two Mediterranean-
diet groups, dietitians held individual and group 
dietary-training sessions at the baseline visit and 
quarterly thereafter. In each session, participants 
completed a 14-item dietary questionnaire to 
assess adherence to the Mediterranean diet8,16 
(Table S4 in the Supplementary Appendix) so 
that personalized advice could be provided to 
the study participants in these groups. Question-
naire scores ranged from 0 to 14, with scores 
lower than 10 defined as low adherence to the 
Mediterranean diet.
Participants in the control group also received 
dietary training at the baseline visit and com-
pleted the 14-item questionnaire at baseline to 
assess their adherence to the Mediterranean diet. 
During the first 3 years of the study, they re-
ceived a leaflet explaining the low-fat diet (see 
page 53 in the Supplementary Appendix) on a 
yearly basis. However, the realization that the 
more infrequent visit schedule and less intense 
support for the control group might be limita-
tions of the study prompted us to amend the 
protocol in October 2006. Thereafter, participants 
who were assigned to the control diet received 
personalized advice and were invited to group 
sessions with the same frequency and intensity 
as those in the Mediterranean-diet groups, with 
the use of a separate 9-item dietary questionnaire 
(Table S5 in the Supplementary Appendix). Scores 
ranged from 0 to 9, with higher scores indicat-
ing greater adherence to a low-fat diet. Except for 
the Site D clinics discussed above and 11 clinics 
at Site I, all clinics of sufficient size delivered all 
three of the interventions (see page 11 in the 
Supplementary Appendix).
A general medical questionnaire, a 137-item 
validated food-frequency questionnaire,17 and the 
Minnesota Leisure-Time Physical Activity Ques-
tionnaire were administered on a yearly basis.13 
Information from the food-frequency questionnaire 
was used to estimate intake of energy and nutri-
ents. Weight, height, and waist circumference were 
directly measured annually.18 Biomarkers of ad-
herence, including urinary hydroxytyrosol levels 
(to confirm adherence in the group receiving extra-
virgin olive oil) and plasma alpha-linolenic acid 
levels (to confirm adherence in the group receiv-
ing mixed nuts), were measured in random sub-
samples of participants at 1, 3, and 5 years (Figs. 
S9 and S10 in the Supplementary Appendix).
End Points
The primary end point was a composite of myo-
cardial infarction, stroke, and death from car-
diovascular causes. Secondary end points were 
stroke, myocardial infarction, death from car-
diovascular causes, and death from any cause. 
We used four sources of information to identify 
end points: repeated contacts with participants, 
contacts with family physicians, a yearly review 
of medical records, and consultation of the Na-
tional Death Index. All medical records that 
were related to end points were examined by the 
end-point adjudication committee, whose mem-
bers were unaware of the intervention-group 
assignments. Only end points that were con-
firmed by the adjudication committee and that 
occurred between June 25, 2003, and December 1, 
2010, were included in the analyses. The criteria 
for adjudicating primary and secondary end 
points are detailed on pages 26 and 27 in the 
Supplementary Appendix.
Statistical Analysis
We initially estimated that a sample of 9000 
participants would be required to provide a sta-
tistical power of 80% to detect a 20% lower risk 
of the primary end point in each Mediterranean-
diet group than in the control-diet group during 
a 4-year follow-up period, assuming an absolute 
cumulative risk of 12% in the control group.13,19 
In April 2008, on the advice of the data and 
safety monitoring board and on the basis of 
lower-than-expected rates of end-point events, 
the sample size was recalculated as 7400 partici-
pants, with the assumption of a 6-year follow-up 
period because of slower-than-expected recruit-
ment and an underlying absolute cumulative risk 
of the primary end point of 8.8% in the control 
group and 6.6% in the Mediterranean-diet groups. 
The relationships between enrollment size and 
statistical power, under several assumptions, 
are shown in Figure S6 in the Supplementary 
Appendix.
Yearly interim analyses began on March 2008 
after a median of 2 years of follow-up. With the 
use of O’Brien–Fleming stopping boundaries, the 
P values for stopping the study at each yearly 
interim analysis were 5×10−6, 0.001, 0.009, and 
0.02 for benefit and 9×10−5, 0.005, 0.02, and 0.05 
for adverse effects.20 The stopping boundary for 
the benefit of the Mediterranean diets with re-
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spect to the primary end point was crossed at 
the fourth interim evaluation; on July 22, 2011, 
the data and safety monitoring board recom-
mended stopping the study on the basis of end 
points documented through December 1, 2010. 
After the study was stopped, we advised all the 
participants, including those in the control group, 
to follow the Mediterranean diet.
The interim and original primary analyses es-
timated differences between the groups assigned 
to different interventions (intention-to-treat analy-
ses). The information on protocol deviations was 
not considered in these analyses. Participants 
were followed from the baseline visit until the 
occurrence of a primary end-point event, death, 
or the last contact date from either medical rec-
ords or study visits. We did not record the date of 
randomization and thus do not report the time 
between randomization and the baseline visit; 
for all the participants, we used the date of the 
baseline visit as time 0 in our analyses. No par-
ticipant had a primary or secondary end-point 
event between randomization and baseline ac-
cording to our review of the medical records.
We constructed Kaplan–Meier cumulative-inci-
dence curves according to intervention group and 
calculated hazard ratios on an intention-to-treat 
basis, with the control group as the reference, 
using a Cox model with indicators for the Medi-
terranean diet with extra-virgin olive oil and the 
Mediterranean diet with nuts. We used robust 
variance estimators to account for intracluster 
correlations in all Cox models, considering as 
clusters the members of the same household and 
the participants in the same clinic of Site D. We 
compared baseline characteristics across the three 
groups and conducted analyses that did not rely 
on the assumption that all the participants were 
randomly assigned and that randomization would 
distribute baseline characteristics of the partici-
pants equally across intervention groups. Our 
main analysis was a multivariable model strati-
fied according to site, sex, and educational level 
(five categories); to account for potential imbal-
ances in baseline risk factors among the inter-
vention groups, the model included nine other 
baseline variables as covariates (see page 12 in 
the Supplementary Appendix). This model was 
also adjusted for propensity scores that used 30 
baseline variables to estimate the probability of 
assignment to each of the intervention groups 
(detailed on pages 12 through 17 in the Supple-
mentary Appendix).
Prespecified subgroup analyses were conduct-
ed according to sex, age, body-mass index (BMI), 
status with respect to cardiovascular risk fac-
tors, and baseline adherence to the Mediterra-
nean diet. In sensitivity analyses, we excluded 
the 1588 participants whose randomization pro-
cedures were known or suspected to have devi-
ated from the protocol: all 652 participants from 
Site D (35 were second members of a household), 
593 participants from Site B (47 were second 
members of a household), and another 343 sec-
ond household members from other sites. In 
addition, we performed sensitivity analyses to 
assess how strong and prevalent an unmeasured 
confounder would have to be to explain the ob-
served results (Table S25 in the Supplementary 
Appendix). We also adjusted for missing data 
and loss to follow-up, implemented other exclu-
sions, and used alternative analytic approaches 
(see pages 30 through 35 and Figs. S2 and S4 in 
the Supplementary Appendix).
A secondary analysis estimated the per-proto-
col effect21 of the Mediterranean diet as compared 
with the control diet that would have been ob-
served if all the participants had adhered to their 
assigned interventions throughout the follow-up 
period. For participants assigned to the Mediter-
ranean-diet groups, adherence was defined as a 
score of 10 or higher on the 14-item question-
naire. For those assigned to the low-fat diet, 
adherence was defined as a fat intake of 30% or 
less of total energy intake according to the food-
frequency questionnaires that were administered 
annually to the three groups or a score or 6 or 
higher on the 9-item questionnaire. We censored 
data for participants when they first stopped ad-
hering to their assigned intervention, estimated 
inverse-probability weights to adjust for postran-
domization prognostic factors, and estimated 
the hazard ratio for an end-point event in the 
Mediterranean-diet groups as compared with the 
low-fat diet group.22,23
The validity of the per-protocol effect estimate 
relies on several assumptions. It assumes that 
loss to follow-up, data collection, and adherence 
can be treated as sequentially randomized at 
each time point, given the measured prognostic 
factors before and after randomization.22 Both 
Mediterranean-diet groups were combined for 
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precision because only 39% of the events re-
mained uncensored after the application of our 
strict definition of adherence. We used the pre-
dicted values from this model after adding a 
product term between intervention and time to 
estimate cumulative-incidence curves (see pages 




From June 25, 2003, through June 30, 2009, a 
total of 8713 candidates were screened for eligi-
bility, and 7447 were assigned to one of the three 
intervention groups (Fig. S7 in the Supplemen-
tary Appendix). Their baseline characteristics 
according to intervention group are shown in 
Table 2, and in Table S23 in the Supplementary 
Appendix. The exclusion of participants whose 
randomization procedures were known to have 
deviated from the protocol did not materially 
change these results. Drug-treatment regimens 
at baseline were similar for participants in the 
three groups, and they continued to be balanced 
during the follow-up period (Table S6 in the 
Supplementary Appendix).
Participants were followed for a median of 
4.8 years (interquartile range, 2.8 to 5.8). After 
the baseline visit, 210 participants (2.8%) chose 
not to attend subsequent visits (1.2% of the par-
ticipants assigned to a Mediterranean diet with 
extra-virgin olive oil, 2.7% of those assigned to 
a Mediterranean diet with nuts, and 4.7% of 
those in the control group). The rate of study 
discontinuation (>2 years since last contact) was 
11.3% in the control group and 4.9% in the 
Mediterranean-diet groups; subsequent follow-up 
was based on reviews of medical records (Fig. S7 
and Table S24 in the Supplementary Appendix). 
Participants who dropped out of the study were, 
on average, 1.4 years younger than those who 
remained in the study and had a higher BMI (the 
weight in kilograms divided by the square of 
height in meters) by 0.4, a higher waist-to-height 
ratio (by 0.01), and a lower score for adherence 
to the Mediterranean diet (by 1.0 points on the 
14-item questionnaire) at baseline.
Adherence to the Dietary Intervention
The scores on the 14-item Mediterranean-diet 
questionnaire increased over the follow-up period 
for the participants in the two Mediterranean-
diet groups (Table S7 and Fig. S8 in the Supple-
mentary Appendix). There were substantial dif-
ferences between the Mediterranean-diet groups 
and the control group in 12 of the 14 items (Table 
S7 in the Supplementary Appendix). Changes in 
biomarkers also indicated good adherence to the 
dietary assignments (Figs. S9 and S10 in the Sup-
plementary Appendix).
Participants in the two Mediterranean-diet 
groups increased weekly servings of fish (by 0.3 
servings) and legumes (by 0.4 servings) in com-
parison with those in the control group (Table 
S8 in the Supplementary Appendix). In addition, 
participants assigned to a Mediterranean diet 
with extra-virgin olive oil and those assigned to 
a Mediterranean diet with nuts increased their 
consumption of extra-virgin olive oil (to 50 and 
32 g per day, respectively) and nuts (to 0.9 and 
6 servings per week, respectively). The main nu-
trient changes in the Mediterranean-diet groups 
reflected the fat content and composition of the 
supplemental foods (Tables S9 and S10 in the 
Supplementary Appendix). No relevant diet-related 
adverse effects were reported (see page 38 in the 
Supplementary Appendix). We found little differ-
ence in changes in physical activity among the 
three groups.
End Points
In the intention-to-treat analysis, there were 96 
primary end-point events in the group assigned 
to a Mediterranean diet with extra-virgin olive 
oil (3.8%), 83 in the group assigned to a Medi-
terranean diet with nuts (3.4%), and 109 in the 
control group (4.4%). The respective incidence 
rates were 8.1, 8.0, and 11.2 per 1000 person-
years, and the 5-year absolute risks were 3.6%, 
4.0%, and 5.7%, respectively (Table 3). The un-
adjusted hazard ratios that used robust variance 
estimators to account for intracluster correlations 
were 0.70 (95% confidence interval [CI], 0.53 to 
0.92) for a Mediterranean diet with extra-virgin 
olive oil and 0.70 (95% CI, 0.53 to 0.94) for a 
Mediterranean diet with nuts as compared with 
the control diet.
Results of our primary analyses that included 
adjustment for propensity scores and 12 baseline 
participant characteristics were similar to those 
of the unadjusted analyses, with hazard ratios of 
0.69 (95% CI, 0.53 to 0.91) for a Mediterranean 
diet with extra-virgin olive oil and 0.72 (95% CI, 
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Characteristic
Mediterranean 
Diet with EVOO 
(N = 2543)
Mediterranean 




Female sex — no. (%)† 1493 (58.7) 1326 (54.0) 1463 (59.7)
Age — yr† 67.0±6.2 66.7±6.1 67.3±6.3
Race or ethnic group — no. (%)‡
White, from Europe 2470 (97.1) 2390 (97.4) 2375 (96.9)
Hispanic, from Central or South America 35 (1.4) 29 (1.2) 38 (1.6)
Other 38 (1.5) 35 (1.4) 37 (1.5)
Smoking status — no. (%)
Never smoked 1572 (61.8) 1465 (59.7) 1527 (62.3)
Former smoker 618 (24.3) 634 (25.8) 584 (23.8)
Current smoker 353 (13.9) 355 (14.5) 339 (13.8)
Body-mass index†§ 29.9±3.7 29.7±3.8 30.2±4.0
Waist circumference — cm 100±10 100±10 101±11
Waist-to-height ratio†¶ 0.63±0.06 0.63±0.06 0.63±0.07
Hypertension — no. (%)‖ 2088 (82.1) 2024 (82.5) 2050 (83.7)
Type 2 diabetes — no. (%)†** 1282 (50.4) 1143 (46.6) 1189 (48.5)
Dyslipidemia — no. (%)†† 1821 (71.6) 1799 (73.3) 1763 (72.0)
Family history of premature CHD — no. (%)‡‡ 576 (22.7) 532 (21.7) 560 (22.9)
Medication use — no. (%)
ACE inhibitors 1236 (48.6) 1223 (49.8) 1216 (49.6)
Diuretics† 534 (21.0) 477 (19.4) 562 (22.9)
Other antihypertensive agents 725 (28.5) 710 (28.9) 758 (30.9)
Statins 1039 (40.9) 964 (39.3) 983 (40.1)
Other lipid-lowering agents 121 (4.8) 145 (5.9) 126 (5.1)
Insulin 124 (4.9) 126 (5.1) 134 (5.5)
Oral hypoglycemic agents† 768 (30.2) 680 (27.7) 757 (30.9)
Antiplatelet therapy 475 (18.7) 490 (20.0) 513 (20.9)
Hormone-replacement therapy§§ 42 (2.8) 35 (2.6) 39 (2.7)
*  Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. ACE denotes angiotensin-
converting enzyme, and EVOO extra-virgin olive oil.
†  P<0.05 for comparisons between groups.
‡  Race and ethnic group were determined by the staff of the trial (nurses or dietitians).
§  The body-mass index is the weight in kilograms divided by the square of the height in meters.
¶  The waist-to-height ratio (an index of central obesity) is the waist circumference divided by height.
‖  Hypertension was defined as a systolic blood pressure of 140 mm Hg or higher, a diastolic blood pressure of 90 mm Hg 
or higher, or the use of antihypertensive therapy.
**  Diabetes was defined as a fasting blood glucose level of 126 mg per deciliter (7.0 mmol per liter) or higher on two 
 occasions, a 2-hour plasma glucose level of 200 mg per deciliter (11.1 mmol per liter) or higher during a 75-g oral 
glucose-tolerance test, or the use of antidiabetic medication.
††  Dyslipidemia was defined as a low-density lipoprotein cholesterol level higher than 160 mg per deciliter (4.1 mmol per 
liter), a high-density lipoprotein cholesterol level of 40 mg per deciliter (1.0 mmol per liter) or lower in men or 50 mg 
per deciliter (1.3 mmol per liter) or lower in women, or the use of lipid-lowering therapy.
‡‡  A family history of premature coronary heart disease (CHD) was defined as a diagnosis of the disease in a male first-
degree relative younger than 55 years of age or in a female first-degree relative younger than 65 years of age.
§§  The values for hormone-replacement therapy are for women only.
Table 2. Baseline Characteristics of the Participants, According to Intervention Group.*
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End Point
Mediterranean 
Diet with EVOO 
(N = 2543)
Mediterranean 




No. of person-yr of follow-up 11852 10365 9763
Primary end point†
No. of events 96 83 109
Incidence rate per 1000 person-yr (95% CI) 8.1 (6.6–9.9) 8.0 (6.4–9.9) 11.2 (9.2–13.5)
5-yr absolute risk — % (95% CI)‡ 3.6 (2.8–4.5) 4.0 (3.1–5.0) 5.7 (4.6–6.9)
Secondary end points
Stroke
No. of events 49 32 58
Incidence rate per 1000 person-yr (95% CI) 4.1 (3.1–5.5) 3.1 (2.1–4.4) 5.9 (4.5–7.7)
5-yr absolute risk — % (95% CI) 1.7 (1.3–2.4) 1.5 (1.1–2.3) 3.0 (2.3–3.9)
Myocardial infarction
No. of events 37 31 38
Incidence rate per 1000 person-yr (95% CI) 3.1 (2.2–4.3) 3.0 (2.0–4.2) 3.9 (2.8–5.3)
5-yr absolute risk — % (95% CI) 1.4 (1.0–2.1) 1.6 (1.1–2.3) 2.1 (1.5–2.9)
Death from cardiovascular causes
No. of events 26 31 30
Incidence rate per 1000 person-yr (95% CI) 2.2 (1.4–3.2) 3.0 (2.0–4.2) 3.1 (2.1–4.4)
5-yr absolute risk — % (95% CI) 1.0 (0.6–1.5) 1.4 (0.9–2.1) 1.6 (1.1–2.3)
Death from any cause
No. of events 118 116 114
Incidence rate per 1000 person-yr (95% CI) 10.0 (8.2–11.9) 11.2 (9.3–13.4) 11.7 (9.6–14.0)
5-yr absolute risk — % (95% CI) 4.4 (3.6–5.4) 5.4 (4.4–6.6) 5.4 (4.4–6.7)
ITT analysis: hazard ratio for each Mediterranean 
diet vs. control (95% CI)§
Primary end point
Unadjusted 0.70 (0.53–0.92) 0.70 (0.53–0.94) 1.00 (ref)
Adjusted¶ 0.69 (0.53–0.91) 0.72 (0.54–0.95) 1.00 (ref)
Secondary end points¶
Stroke 0.65 (0.44–0.95) 0.54 (0.35–0.82) 1.00 (ref)
Myocardial infarction 0.82 (0.52–1.30) 0.76 (0.47–1.25) 1.00 (ref)
Death from cardiovascular causes 0.62 (0.36–1.06) 1.02 (0.63–1.67) 1.00 (ref)
Death from any cause 0.90 (0.69–1.18) 1.12 (0.86–1.47) 1.00 (ref)
ITT analysis: hazard ratio for Mediterranean diets 
combined vs. control (95% CI)§
Primary end point
Unadjusted 0.70 (0.55–0.89) 1.00 (ref)
Adjusted¶ 0.70 (0.55–0.89) 1.00 (ref)
Secondary end points¶
Stroke 0.58 (0.42–0.82) 1.00 (ref)
Myocardial infarction 0.80 (0.53–1.21) 1.00 (ref)
Death from cardiovascular causes 0.80 (0.51–1.24) 1.00 (ref)
Death from any cause 0.98 (0.77–1.24) 1.00 (ref)
Table 3. Estimates of Cardiovascular Events, According to Intervention Group.*
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0.54 to 0.95) for a Mediterranean diet with nuts 
(Fig. 1A and Table 3). There were similar results 
on three alternative analyses: one that was ad-
justed with inverse-probability weighting (mod-
els 3A through 3C in Fig. S2 in the Supplemen-
tary Appendix), one that included adjustments 
for the Framingham risk score24 (models 6A 
through 6C in Fig. S2 in the Supplementary Ap-
pendix), and one that omitted participants 
known or suspected to have been assigned to an 
intervention group without individual random-
ization (Table 3 and Figs. 2 and 3, and Figs. S2 
and S4 in the Supplementary Appendix). The 
results for secondary end points are shown in 
Table 3 and Figure 1B.
To provide an alternative, noncausal explana-
tion of the observed association (i.e., to change 
the point estimate of the hazard ratio to ≥1.0), 
an unmeasured binary confounder would need 
to be present in at least 40% of the control group 
but in less than 25% of each Mediterranean-diet 
group and be associated with a relative risk of 
more than 4 for the primary end point. For fur-
ther details, see Table S25 in the Supplementary 
Appendix.
To explore the effect of the October 2006 
protocol change that was implemented for the 
control group to intensify nutritional counsel-
ing, we conducted separate analyses of the par-
ticipants recruited before the protocol change 
and those recruited after the protocol change. 
The hazard ratios for the Mediterranean diet 
(both groups merged) as compared with the 
control diet were 0.77 (95% CI, 0.59 to 1.00) for 
the participants recruited before October 2006 
and 0.49 (95% CI, 0.26 to 0.92) for those re-
cruited in October 2006 or later (P = 0.21 for 
heterogeneity).
The per-protocol (adherence-adjusted) hazard 
ratio for the primary end point was 0.42 (95% 
CI, 0.24 to 0.63) for the Mediterranean diet as 
compared with the control diet (Fig. 3); the esti-
mated absolute differences in incidence between 
the combined Mediterranean-diet groups and 
End Point
Mediterranean 
Diet with EVOO 
(N = 2543)
Mediterranean 




Primary end point, excluding Site D and second 
household members‖
Each Mediterranean diet and control
No. of participants 2158 2109 2138
5-year absolute risk — % (95% CI) 3.4 (2.6–4.3) 3.9 (3.0–5.0) 5.9 (4.8–7.2)
Hazard ratio (95% CI)¶ 0.66 (0.49–0.89) 0.64 (0.47–0.88) 1.00 (ref)
Mediterranean diets combined and control
5-year absolute risk — % (95% CI) 3.6 (3.0–4.3) 5.9 (4.8–7.2)
Hazard ratio (95% CI)¶ 0.65 (0.50–0.85) 1.00 (ref)
*  CI denotes confidence interval, and ref reference.
†  The primary end point was a composite of myocardial infarction, stroke, and death from cardiovascular causes.
‡  In the combined Mediterranean-diet groups, the 5-year absolute risk of the primary end point was 3.8% (95% CI, 3.2  
to 4.4).
§  The intention-to-treat (ITT) analysis included all 7447 participants.
¶  The Cox model was stratified according to sex, recruiting site, and educational level (five categories) and adjusted for 
age (continuous variable), smoking status (never smoked, former smoker, or current smoker), hypertension at baseline 
(yes or no), dyslipidemia at baseline (yes or no), diabetes at baseline (yes or no), family history of premature coronary 
heart disease (yes or no), body-mass index (continuous variable), waist-to-height ratio (continuous variable), physical 
activity (in quintiles), and propensity scores that used 30 baseline variables to estimate the probability of assignment  
to each of the intervention groups (see pages 12 through 17 in the Supplementary Appendix). Robust standard errors to 
account for intracluster correlations were used.
‖  The analysis included 6405 participants. Excluded were second members of the same household (425 participants) and 
participants from Site D (617 participants). When participants from Site B were also excluded, the sample size was 
5859 and the adjusted hazard ratios were 0.71 (95% CI, 0.52 to 0.97) for the group assigned to a Mediterranean diet 
with extra-virgin olive oil, 0.68 (95% CI, 0.49 to 0.95) for the group assigned to a Mediterranean diet with nuts, and 
0.69 (95% CI, 0.53 to 0.92) for the combined Mediterranean-diet groups, with the group assigned to a control diet as 
the reference.
Table 3. (Continued.)
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the control group were 0.67, 1.38, and 2.00 per-
centage points at 12, 24, and 36 months after 
enrollment, respectively (see pages 36 through 
38 in the Supplementary Appendix). The results 
of additional sensitivity and subgroup analyses 
were also consistent with the results of our pri-
mary analyses (Figs. 2 and 3, and Figs. S2, S4, 
and S12 in the Supplementary Appendix).
Discussion
In this study involving high-risk persons without 
cardiovascular disease, assignment to an energy-
unrestricted Mediterranean diet supplemented 
with either extra-virgin olive oil or nuts was asso-
ciated with a lower risk of major cardiovascular 
events over a period of 5 years than assignment 
to a control (low-fat) diet, with a relative differ-
ence of 30% and an absolute difference of 1.7 to 
2.1 percentage points. Our analysis, which in-
corporated information about adherence to the 
diets, suggests that the difference in rates of 
cardiovascular events between those assigned to 
the Mediterranean diets and those assigned the 
control diet was greater among participants with 
better adherence. These results support previously 
reported benefits of the Mediterranean diet for 
cardiovascular risk reduction from a randomized 
trial.4,25,26 Our findings are also consistent with 
those of previous observational studies.2,5,23,25-33 
Table S11 in the Supplementary Appendix sum-
marizes the findings from systematic reviews on 
this issue.
In response to a 2017 report11 suggesting 
that distributions of baseline variables in the 
PREDIMED trial were significantly different from 
what would have been expected to result from 
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Figure 1. Kaplan–Meier Estimates of the Cumulative 
 Incidence of End-Point Events in the Total Study 
 Population.
Panel A shows the incidence of the primary end point 
(a composite of acute myocardial infarction, stroke, 
and death from cardiovascular causes), and Panel B 
shows total mortality. The insets show the same data 
on an expanded y axis. Hazard ratios were stratified 
according to sex, recruiting site, and educational level 
(five categories) and adjusted for age (continuous vari-
able), smoking (never smoked, former smoker, or cur-
rent smoker), hypertension (yes or no), dyslipidemia 
(yes or no), diabetes (yes or no), family history of pre-
mature coronary heart disease, body-mass index (con-
tinuous variable), waist-to-height ratio (continuous 
variable), physical activity (in quintiles), and propensity 
scores that estimated the probability of assignment to 
each intervention group on the basis of 30 baseline 
variables (see pages 12 through 17 in the Supplemen-
tary Appendix). Robust standard errors to account for 
intracluster correlations were used. CI denotes confi-
dence interval, EVOO extra-virgin olive oil, and Med 
Mediterranean.
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of the documentation and data at the 11 recruit-
ment sites. After sharing this information with 
the editors of the Journal, we withdrew our 
original report of this trial and now publish this 
new report. Despite some departures from the 
randomization protocol, most of the baseline 
covariates were balanced across groups, and 
there was no meaningful difference in the pre-
dicted risks of future cardiovascular events 
across the three groups (Fig. S13 in the Supple-
mentary Appendix).
We reanalyzed the data using methods that 
do not rely exclusively on the assumption that all 
the participants had been randomly assigned to 
intervention groups and that adjusted for base-
line characteristics and propensity scores estimat-
ing probabilities of assignment to each interven-
tion on the basis of 30 baseline covariates. The 
results of our reanalyses (Figs. 2 and 3 and Ta-
ble 3, and Figs. S2 and S4 in the Supplementary 
Appendix) were similar to the results that we 
originally reported. In addition, reanalyses of 
our data did not reveal any evidence that certain 
lifestyle or treatment factors that are potentially 
related to the risk of cardiovascular disease either 
biased the results or might provide an alternative 
explanation for the observed benefits of the 
Mediterranean-diet interventions on cardiovascu-
lar disease. Analyses that excluded participants 
whose assignment to an intervention group was 
known or suspected not to have followed the 
randomization protocol (participants from Sites D 
and B and second household members) yielded 
results consistent with the results of our pri-
mary analysis.
The retention rate was higher in the group 
Figure 2. Sensitivity Analyses of Each Mediterranean-Diet Group and the Control Group.
Shown are hazard ratios for the primary end point in each Mediterranean-diet group as compared with the control 
group, with estimates based on different analytic approaches or exclusions. Hazard ratios were stratified according 
to sex, recruiting site, and educational level (five categories) and (with the exception of the unadjusted intention-to-
treat [ITT] analysis) were adjusted for age, smoking (never smoked, former smoker, or current smoker), hyperten-
sion (yes or no), dyslipidemia (yes or no), diabetes (yes or no), family history of premature coronary heart disease, 
body-mass index (continuous variable), waist-to-height ratio (continuous variable), and physical activity (in quintiles). 
In addition, all multivariable models were adjusted for propensity scores that estimated the probability of assign-
ment to each intervention group on the basis of 30 baseline variables. We used robust standard errors to account 
for intracluster correlations. One analysis excluded all the participants from Site D (652 participants) and all second 
members of the same household (425 participants, including 35 from Site D); in total, 1042 participants were ex-
cluded from this analysis. Another analysis excluded all the participants from Site D (652 participants), all the par-
ticipants from Site B (593 participants), and all second members of the same household (425 participants, includ-
ing 35 from Site D and 47 from Site B); in total, 1588 participants were excluded from this analysis. The results of 
additional sensitivity analyses are shown in Figures S2 and S4 in the Supplementary Appendix.
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assigned to a Mediterranean diet with extra-virgin 
olive oil than in the other two groups (the group 
assigned to a Mediterranean diet with nuts and 
the control group). These two groups were also 
slightly smaller in size, which resulted in a larger 
number of person-years of follow-up in the group 
assigned to a Mediterranean diet with extra-virgin 
olive oil. The different follow-up had the poten-
tial to bias the incidence rates toward lower rates 
in the group assigned to a Mediterranean diet 
with extra-virgin olive oil. However, analyses 
that used multiple imputation and inverse-prob-
ability weighting to adjust for a potential selec-
tion bias due to differential losses to follow-up 
yielded estimates consistent with the main analy-
sis (see pages 30 through 35 and Fig. S4 in the 
Supplementary Appendix). An additional limita-
tion of our study is that participants were at high 
cardiovascular risk; whether the results can be 
generalized to persons at lower risk requires 
further research.
As with many clinical trials, the observed rates 
of cardiovascular events were lower than antici-
pated, with reduced statistical power to separately 
assess components of the primary end point. 
However, favorable trends were seen for both 
stroke and myocardial infarction. It is possible, 
but not likely, that some cardiovascular events 
were not detected (see pages 28 and 29 in the 
Supplementary Appendix).
Even though participants in the control group 
received advice to reduce fat intake, changes in 
total fat on the food-frequency questionnaire 
were small and the largest differences at the end 
of the study were in the distribution of fat sub-
types. The interventions were intended to im-
prove the overall dietary pattern, but the major 
between-group differences involved the supple-
mental items, extra-virgin olive oil and nuts. 
Differences were also observed in the consump-
tion of fish and legumes but not in the consump-
tion of other food groups. (It is worth noting 
that on the 14-item Mediterranean-diet question-
naire, there were substantial between-group differ-
ences in 12 of the 14 items.) The modest between-
group differences according to the food-frequency 
questionnaire can be explained by the facts that 
most study participants had been consuming a 
baseline diet similar to the study Mediterranean 
diet and that the control group was given recom-
mendations for a healthy diet, factors that raise 
the question of how applicable our results may be 
to high-risk persons in other countries. Answer-
ing this question will require further research.3
In conclusion, in this primary prevention study 
involving persons at high risk for cardiovascular 
events, those assigned to an energy-unrestricted 
Mediterranean diet, supplemented with extra-
virgin olive oil or nuts, had a lower rate of major 
cardiovascular events than those assigned to a 
Figure 3. Sensitivity Analyses of the Combined Mediterranean-Diet Groups and the Control Group.
Shown are hazard ratios for the primary end point in the combined Mediterranean-diet groups as compared with 
the control group, with estimates based on different analytic approaches or exclusions. Hazard ratios were stratified 
according to sex, recruiting site, and educational level (five categories) and (with the exception of the unadjusted 
ITT analysis) were adjusted for age, smoking (never smoked, former smoker, or current smoker), hypertension (yes 
or no), dyslipidemia (yes or no), diabetes (yes or no), family history of premature coronary heart disease, body-mass 
index (continuous variable), waist-to-height ratio (continuous variable), and physical activity (in quintiles). In addi-
tion, all multivariable models were adjusted for propensity scores, and we used robust standard errors to account 
for intracluster correlations.
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reduced-fat diet. Our findings support a benefi-
cial effect of the Mediterranean diet for the pri-
mary prevention of cardiovascular disease.
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